MEDIROM Healthcare Technologies Inc. Reports Financial Results for the Year Ending 2020 and Provides Corporate Update
MEDIROM Healthcare Technologies Inc. (MRM) reported FY 2020 financial results with total revenue decreasing by 14.5% to $32.4 million, primarily due to COVID-19 lockdowns. The net loss stood at $5 million, with Adjusted EBITDA at -16.3%. SG&A expenses increased 22.6%impairment loss by 139.1%$13.8 million, aided by proceeds from the IPO.
- Cash flow from financing activities was positive at $13.8 million.
- Net cash increased by $8.9 million in FY2020.
- Acquisition of a medium-sized salon in May 2021 demonstrates ongoing growth.
- Total revenue decreased by 14.5% to $32.4 million.
- Net loss recorded at $5 million due to COVID-19 impacts.
- SG&A expenses increased by 22.6% mainly due to office relocation and IPO costs.
- Impairment loss increased significantly by 139.1%.
Conference Call to be held Monday May 17, 2021 at 4:30 p.m. ET
NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM, “MEDIROM”), a leading holistic health services provider in Japan, today announced MEDIROM’s financial results for the year ended December 31, 2020.
FY 2020 Financial Highlights
- Total revenue decreased by
14.5% to$32.4 million , due to the COVID-19 lock-down in April and May 2020. - Cost of revenues stayed relatively flat as a result of an increase in the total number of salons from 283 to 290, offset by cost reduction efforts to mitigate the impact of COVID-19.
- SG&A increased by
22.6% due to the office relocation and IPO expenses/costs. - Impairment loss increased
139.1% as certain salons with relatively long contract terms of leases and large amounts of asset retirement costs were impaired. - Net loss of
$5 million recorded due to the COVID-19 halt and temporarily increased SG&A. - Adjusted EBITDA and Adjusted EBITDA margin were negative
$5.3 million and minus16.3% , respectively. - Cashflow from Operating Activities was negative
$3.5 million , mainly due to the decrease in net income. - Cashflow from Investing Activities was negative
$1.3 million , primarily due to salons acquisitions from franchisees. - Cashflow from Financing Activities was positive
$13.8 million , due to$11.3 million in proceeds from the IPO and the special long-term bank loans for the COVID-19 pandemic. - Net cash increased by
$8.9 million in FY2020.
Corporate Highlights FY 2020
- The revenue decrease in System-Wide Sales was observed only from March to May due to the first COVID-19 Declaration of Emergency in operation in Tokyo metropolis and several prefectures.
- KPIs recovered after the first COVID-19 Declaration.
- Our mobile application LavⓇ is being upgraded for general consumers use on top of the engagement by Specific Guidance Program.
- Currently developing a self-charging smart bracelet, MOTHER TrackerⓇ, with a silicon valley start-up, Matrix Industries. Its major features are chargeless generator, boost converter, and Software Development Kit open policy.
- Preparing for the integration of the hashed health data collected at our salons, via mobile application and smart tracker.
Outlook and perspective FY 2021
- We are currently experiencing the third Declaration of Emergency for COVID-19 in major prefectures and cities.
- After observing the KPIs transition in FY2020 and ongoing FY2021, we concluded that our industry is regarded as a necessary service for people’s daily life. We believe that relaxation salon business segment will continue to stay stable, and that we can generate reasonable profit by controlling the cost and expenses.
- Acquired a medium sized salon in May 2021. We will actively continue to grow our salon business through M&A transactions.
- Intend for the MOTHER TrackerⓇ to be launched before the end of the year.
Financial Results for the Year Ended December 31, 2020 Compared to 2019
Revenues
Revenues derived from our Relaxation Salon Segment were JPY3,864,656 thousand (US
The revenue from our Relaxation Salon Segment consists of revenue from directly-operated salons and revenue from franchising. In the year ended December 31, 2019, our revenue from directly-operated salons and from franchising was JPY2,031,155 thousand (US
The primary factor for the decrease in revenues from directly-operated salons between year end 2019 and 2020 was the decrease in the number of customers due to the COVID-19 pandemic. In the year ended December 31, 2019, our salons had customer visits of 857 thousand, while in the same period of 2020, the figure was 650 thousand excluding visitors to our JOYHANDS WELLNESS salons located in spa facilities (for which data is not available).
The primary reason for the decrease in revenues from franchising was also the decrease in the number of customers due to the COVID-19 pandemic. In the year ended December 31, 2019, our franchised salons had served 302.9 thousand customers, while in the same period of 2020, franchised salons served 187.5 thousand customers. Although this decrease in revenue by our franchisees resulted in less royalty income for the Company, our expenses for providing supporting services to our franchisees decreased accordingly.
We recognize revenue from initial franchise membership on the opening date of the new franchised salons. In addition, our revenue from franchise royalties includes revenues from recurring royalty income, rental income from subleased salon properties, construction of franchised salons, uniforms and training sales.
The revenue from our Preventative Healthcare Segment decreased
Cost of Revenues
For the year ended December 31, 2019 and 2020, the cost of revenues was JPY 2,957,506 thousand (US
The cost of revenue from directly-operated salon increased by JPY236,950 thousand (US
Selling, General, and Administration Expenses
For the year ended December 31, 2019 and 2020, the selling, general, and administration expenses were JPY871,862 thousand (US
Impairment Loss on Long-lived Assets
MD, BEW and DW recorded impairment losses of JPY30,224 thousand (US
Interest Expense
Interest expense was relatively flat in 2020 compared with that of 2019.
Gain from Bargain Purchase
Gain from bargain purchases through acquisitions of relaxation salons decreased by JPY6,487 thousand (US
Other Income—Net
Other income increased in 2020 by JPY127,146 thousand (US
Income Tax Expense
Income tax benefit for 2020 was JPY87,519 thousand (US
Net Income and Adjusted EBITDA
Our consolidated net income in the year ended December 31, 2019 was JPY17,335 thousand (US
Cash Flows
The following table sets forth a summary of our cash flows for the periods indicated.
Year ended December 31, | ||||||||||||
2020($) | 2020(¥) | 2019(¥) | ||||||||||
Net (loss) income attributable to shareholders | $ | (5,225 | ) | ¥ | (539,170 | ) | ¥ | 17,335 | ||||
Net cash provided by operating activities | (3,551 | ) | (366,420 | ) | 7,870 | |||||||
Net cash used in investing activities | (1,353 | ) | (139,599 | ) | (37,931 | ) | ||||||
Net cash provided by financing activities | 13,879 | 1,432,131 | 331,994 | |||||||||
Net increase of cash and cash equivalents during the period | 8,975 | 926,112 | 301,933 | |||||||||
Cash and cash equivalents at beginning of period | $ | 4,977 | ¥ | 513,621 | ¥ | 211,688 | ||||||
Cash and cash equivalents at end of period | $ | 13,952 | ¥ | 1,439,733 | ¥ | 513,621 | ||||||
Operating Activities
Net cash flows provided by operating activities decreased from JPY7,870 thousand (US
Investing Activities
Net cash flows used in investing activities increased from JPY37,931 thousand (US
The total amount of capital investment made in the year ended December 31, 2020 was JPY203,320 thousand (US
Financing Activities
Net cash flows from financing activities increased from JPY331,994 thousand (US
Conference Call Access
Management will host a conference call on Monday, May 17, 2021 at 4:30 p.m. ET to review financial results and provide an update on corporate developments. Following management’s formal remarks there will be a question-and-answer session.
A presentation accompanying the conference call is available in the investor relations section of MEDIROM’s website at https://medirom.co.jp/pdf_file/open/146/FY2020_Investor_Presentation_Slide or at https://medirom.co.jp/en/ir/news/20210518/146.
Participants are asked to pre-register for the call via the following link: https://dpregister.com/sreg/10154723/e6b6b888e7
Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-866-777-2509 (domestic) or 1-412-317-5413 (international), Japan Toll Free 0066-33-1-33094. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the MEDIROM call.
The conference call will be available through a live webcast at the following link: https://services.choruscall.com/links/mrm210429.html
A webcast replay of the call will be available approximately one hour after the end of the call through August 17, 2021. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10154723. A telephonic replay of the call will be available through May 31, 2021.
FORWARD-LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
Non-GAAP Financial Measures
This press release includes non-GAAP financial metrics that we use to help us evaluate our business, identify trends affecting our business, formulate business plans, and make strategic decisions. Adjusted EBITDA and Adjusted EBITDA Margin are financial measures that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America ("GAAP"). Definitions for such non-GAAP measures can be found in the Appendix to this presentation. Any non-GAAP financial measures used in this presentation are in addition to, and not meant to be considered superior to, or a substitute for, the Company's financial statements prepared in accordance with GAAP. A reconciliation of each of these non-GAAP measures to their nearest GAAP measure is set forth in the Appendix to this presentation.
The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. The Company's management uses these non-GAAP measures to compare our performance to that of prior periods for trend analyses and for budgeting and planning purposes. These measures are used in monthly financial reports prepared for management and our board of directors. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in com paring our financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in our financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. Undue reliance should not be placed on these measures as the Company's only measures of operating performance, nor should such measures be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP. Non-GAAP financial measures as used in respect of the Company may not be comparable to similarly titled amounts used by other companies.
(1) For a reconciliation of Adjusted EBITDA to net income (loss), the most comparable U.S. GAAP measure, see the following table.
Reconciliation of non-GAAP measures: | Year ended December 31, | ||||||||||||||
(in thousands, except Adjusted EBITDA margin) | 2020($) | 2020(¥) | 2019(¥) | ||||||||||||
Net (loss) income | $ | (5,225 | ) | ¥ | (539,170 | ) | ¥ | 17,335 | |||||||
Dividend income and interest income | (13 | ) | (1,334 | ) | (1,338 | ) | |||||||||
Interest expense | 128 | 13,234 | 13,591 | ||||||||||||
Gain from bargain purchases | — | — | (6,487 | ) | |||||||||||
Other, net | (1,272 | ) | (131,299 | ) | (4,153 | ) | |||||||||
Income tax expense | (848 | ) | (87,519 | ) | 15,961 | ||||||||||
Equity in earnings (loss) of investment | — | — | (559 | ) | |||||||||||
Operating income | $ | (7,230 | ) | ¥ | (746,088 | ) | ¥ | 34,350 | |||||||
Depreciation and amortization | 604 | 62,290 | 46,174 | ||||||||||||
Losses on sales of directly-operated salons to franchises | — | — | 9,600 | ||||||||||||
Losses on disposal of property and equipment, net and other intangible assets, net | 328 | 33,841 | 4,631 | ||||||||||||
Impairment loss on long-lived assets | 1,031 | 106,501 | 44,546 | ||||||||||||
Adjusted EBITDA | $ | (5,267 | ) | ¥ | (543,456 | ) | ¥ | 139,301 | |||||||
Adjusted EBITDA margin | (16.3 | ) | % | (16.3 | ) | % | 3.6 | % | |||||||
(2) Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA for a period by total revenue for the same period.
About MEDIROM Healthcare Technologies Inc.
MEDIROM operates 303 (as of March 31, 2021) relaxation salons across Japan, Re.Ra.KuⓇ, being its leading brand, and provides healthcare services. In 2015, MEDIROM entered the health-tech business, and launched new healthcare programs using on-demand training app called "LavⓇ", which is developed by the company. MEDIROM also entered the device business in 2020 and is developing a smart tracker "MOTHER TrackerⓇ". MEDIROM plans to expand the scope of its business to include data analysis utilizing the data it has collected since formation of the company.
URL : https://medirom.co.jp/en
Contacts:
Investor Relations Team
ir@medirom.co.jp
MEDIROM HEALTHCARE TECHNOLOGIES INC. | ||||||||
CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2020 AND 2019 (Yen in thousands, except share data) | ||||||||
December 31, | ||||||||
2020 | 2019 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | ¥ | 1,439,733 | ¥ | 513,621 | ||||
Time deposits | 32,524 | 38,520 | ||||||
Accounts receivable-trade, net | 148,540 | 337,048 | ||||||
Accounts receivable-other | 411,278 | 428,278 | ||||||
Due from shareholder | ― | 8,266 | ||||||
Inventories | 7,956 | 5,511 | ||||||
Prepaid expenses and other current assets | 47,193 | 47,485 | ||||||
Total current assets | 2,087,224 | 1,378,729 | ||||||
Property and equipment, net | 235,930 | 168,955 | ||||||
Goodwill | 150,720 | 78,282 | ||||||
Other intangible assets, net | 97,615 | 77,638 | ||||||
Investments | 500 | 14,044 | ||||||
Long-term accounts receivable-other, net | 116,942 | 106,208 | ||||||
Right-of-use asset - operating lease, net | 1,578,828 | 1,829,968 | ||||||
Lease and guarantee deposits | 710,636 | 769,104 | ||||||
Deferred tax assets, net | 655,591 | 222,505 | ||||||
Deferred offering costs | ― | 57,509 | ||||||
Other assets | 79,480 | 54,523 | ||||||
Total assets | ¥ | 5,713,466 | ¥ | 4,757,465 | ||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | ¥ | 67,016 | ¥ | 122,590 | ||||
Accrued expenses | 889,112 | 447,974 | ||||||
Short-term borrowings and current portion of long-term borrowings | 242,281 | 371,570 | ||||||
Accrued income taxes | 43,198 | 17,834 | ||||||
Contract liability (current) | 172,063 | ― | ||||||
Advances received | 461,665 | 483,124 | ||||||
Short-term lease liability | 658,320 | 704,024 | ||||||
Other current liabilities | 118,933 | 115,573 | ||||||
Total current liabilities | 2,652,588 | 2,262,689 | ||||||
Long-term borrowings - net of current portion | 668,380 | 150,531 | ||||||
Deposit received | 375,463 | 474,388 | ||||||
Long-term contract liability - net of current portion | 333,978 | ― | ||||||
Long-term lease liability - net of current portion | 992,892 | 1,136,799 | ||||||
Asset retirement obligation | 191,192 | 127,411 | ||||||
Other liabilities | 7,716 | 5,589 | ||||||
Total liabilities | 5,222,209 | 4,157,407 | ||||||
COMMITMENTS AND CONTINGENCIES (NOTE 18) | ||||||||
SHAREHOLDERS’ EQUITY: | ||||||||
Common stock, no par value; 9,999,999 shares authorized; 4,915,000 shares issued and 4,822,500 shares outstanding at December 31, 2020; 4,115,000 shares issued and 4,022,500 shares outstanding at December 31, 2019 | 1,179,313 | 595,000 | ||||||
Class A common stock, no par value; 1 share authorized; 1 share issued and 1 share outstanding at December 31, 2020 and 2019 | 100 | 100 | ||||||
Treasury stock, at cost- 92,500 common shares at December 31, 2020 and 2019 | (3,000 | ) | (3,000 | ) | ||||
Additional paid-in capital | 1,018,146 | 713,267 | ||||||
Accumulated deficit | (1,703,302 | ) | (705,309 | ) | ||||
Total shareholders' equity | 491,257 | 600,058 | ||||||
Total liabilities and shareholders' equity | ¥ | 5,713,466 | ¥ | 4,757,465 | ||||
MEDIROM HEALTHCARE TECHNOLOGIES INC. | ||||||||
CONSOLIDATED STATEMENTS OF (LOSS) INCOME FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 (Yen in thousands, except share and per share data) | ||||||||
Years Ended December 31, | ||||||||
2020 | 2019 | |||||||
Revenues: | ||||||||
Revenue from directly-operated salons | ¥ | 2,026,806 | ¥ | 2,031,155 | ||||
Franchise revenue | 1,289,141 | 1,833,501 | ||||||
Other revenues | 25,670 | 43,608 | ||||||
Total revenues | 3,341,617 | 3,908,264 | ||||||
Cost of revenues and operating expenses: | ||||||||
Cost of revenue from directly-operated salons | 2,149,843 | 1,912,893 | ||||||
Cost of franchise revenue | 745,102 | 1,019,956 | ||||||
Cost of other revenues | 17,722 | 24,657 | ||||||
Selling, general and administrative expenses | 1,068,537 | 871,862 | ||||||
Impairment loss on long-lived assets | 106,501 | 44,546 | ||||||
Total cost of revenues and operating expenses | 4,087,705 | 3,873,914 | ||||||
Operating (loss) income | (746,088 | ) | 34,350 | |||||
Other income (expense): | ||||||||
Dividend income | 2 | 2 | ||||||
Interest income | 1,332 | 1,336 | ||||||
Interest expense | (13,234 | ) | (13,591 | ) | ||||
Gain from bargain purchases | ― | 6,487 | ||||||
Subsidies | 111,581 | ― | ||||||
Other, net | 19,718 | 4,153 | ||||||
Total other income (expense) | 119,399 | (1,613 | ) | |||||
(Loss) income before income tax (benefit) expense and equity in earnings of investment | (626,689 | ) | 32,737 | |||||
Income tax (benefit) expense | (87,519 | ) | 15,961 | |||||
Equity in earnings of investment | ― | 559 | ||||||
Net (loss) income | ¥ | (539,170 | ) | ¥ | 17,335 | |||
Net (loss) earnings per share | ||||||||
Basic | ¥ | (133.97 | ) | ¥ | 4.63 | |||
Diluted | ¥ | (133.97 | ) | ¥ | 4.06 | |||
Weighted average shares outstanding | ||||||||
Basic | 4,024,692 | 3,747,296 | ||||||
Diluted | 4,024,692 | 4,272,302 | ||||||
MEDIROM HEALTHCARE TECHNOLOGIES INC. | ||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 (Yen in thousands) | ||||||||
Years Ended December 31, | ||||||||
2020 | 2019 | |||||||
Cash flows from operating activities: | ||||||||
Net (loss) income | ¥ | (539,170 | ) | ¥ | 17,335 | |||
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||||||||
Depreciation and amortization | 62,290 | 46,174 | ||||||
Losses on sales of directly-operated salons to franchisees | ― | 9,600 | ||||||
Allowance for doubtful accounts | (11,376 | ) | 271 | |||||
Impairment loss on investments | 10,544 | ― | ||||||
Losses on disposal of property and equipment, net and other intangible assets, net | 33,841 | 4,631 | ||||||
Impairment loss on long-lived assets | 106,501 | 44,546 | ||||||
Gain from bargain purchases | ― | (6,487 | ) | |||||
Deferred income tax (benefit) expense | (107,264 | ) | 5,739 | |||||
Other non-cash (gains) expense – net | 1,903 | (895 | ) | |||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable-trade, net | 189,143 | (66,877 | ) | |||||
Accounts receivable-other | (48,031 | ) | (36,190 | ) | ||||
Inventories | (2,445 | ) | 892 | |||||
Prepaid expenses and other current assets | (8,167 | ) | (39,698 | ) | ||||
Lease and guarantee deposits | 58,468 | (14,163 | ) | |||||
Accounts payable | (55,574 | ) | (18,729 | ) | ||||
Accrued expenses | 206,706 | 116,856 | ||||||
Accrued income taxes | 25,364 | 4,200 | ||||||
Contract liability | (160,595 | ) | ― | |||||
Advances received | (15,322 | ) | (39,177 | ) | ||||
Other current liabilities | (3,389 | ) | 10,226 | |||||
Deposit received | (98,925 | ) | (20,871 | ) | ||||
Other assets and other liabilities – net | (10,922 | ) | (9,513 | ) | ||||
Net cash (used in) provided by operating activities | (366,420 | ) | 7,870 | |||||
Cash flows from investing activities: | ||||||||
Purchases of time deposits | (26,703 | ) | (37,900 | ) | ||||
Proceeds from maturities of time deposits | 10,000 | 6,000 | ||||||
Proceeds from sale of investments | 53,000 | ― | ||||||
Acquisition of investment securities | ― | (13,544 | ) | |||||
Acquisition of property and equipment | (73,556 | ) | (7,406 | ) | ||||
Proceeds from sale of property and equipment | 3,227 | 5,000 | ||||||
Cost additions to internal use software | (30,569 | ) | (12,068 | ) | ||||
Acquisition of businesses – net of cash acquired | (99,195 | ) | (3,201 | ) | ||||
Proceeds from due from shareholder | 8,267 | 8,412 | ||||||
Payment received on short-term loans receivable | 900 | 450 | ||||||
Payment received on long-term accounts receivable-other, net | 15,030 | 16,326 | ||||||
Net cash used in investing activities | ¥ | (139,599 | ) | ¥ | (37,931 | ) |
FAQ
What were the key financial results for MEDIROM (MRM) in FY 2020?
How did COVID-19 impact MEDIROM's revenue?
What was MEDIROM's Adjusted EBITDA for FY 2020?